| Michael W Piepkorn, MD | |
|
2330 130th Ave Ne Ste 201, Bellevue, WA 98005-1756 | |
| (425) 455-9945 | |
| (425) 455-9947 |
| Full Name | Michael W Piepkorn |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 51 Years |
| Location | 2330 130th Ave Ne Ste 201, Bellevue, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609975226 | NPI | - | NPPES |
| 7099864 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | MD00014558 (Washington) | Secondary |
| 207ND0900X | Dermatology - Dermatopathology | MD00014558 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dermatopatholoty Northwest Pllc | 3173516101 | 5 |
News Archive
Some businesses are taking advantage of the health law's requirements as states prepare to implement it.
The Bill & Melinda Gates Foundation is "to give $220 million over five years to the non-profit biotech firm Aeras to develop vaccines to fight tuberculosis [TB], a company statement said Thursday," Agence France-Presse reports (3/15).
"I know I need this medicine to help lower my chance of cancer recurrence, but it makes my joints ache and stiff. It makes me feel old and I am not sure I can take this medication much longer."
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).
Researchers from Universidad Politécnica de Madrid have developed a new tool that provides standard and shared clinico-genomic data among European healthcare institutions.
› Verified 7 days ago
| Entity Name | Dermatopatholoty Northwest Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932296092 PECOS PAC ID: 3173516101 Enrollment ID: O20040406000834 |
News Archive
Some businesses are taking advantage of the health law's requirements as states prepare to implement it.
The Bill & Melinda Gates Foundation is "to give $220 million over five years to the non-profit biotech firm Aeras to develop vaccines to fight tuberculosis [TB], a company statement said Thursday," Agence France-Presse reports (3/15).
"I know I need this medicine to help lower my chance of cancer recurrence, but it makes my joints ache and stiff. It makes me feel old and I am not sure I can take this medication much longer."
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).
Researchers from Universidad Politécnica de Madrid have developed a new tool that provides standard and shared clinico-genomic data among European healthcare institutions.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael W Piepkorn, MD 2330 130th Ave Ne Ste 201, Bellevue, WA 98005-1756 Ph: (425) 455-9945 | Michael W Piepkorn, MD 2330 130th Ave Ne Ste 201, Bellevue, WA 98005-1756 Ph: (425) 455-9945 |
News Archive
Some businesses are taking advantage of the health law's requirements as states prepare to implement it.
The Bill & Melinda Gates Foundation is "to give $220 million over five years to the non-profit biotech firm Aeras to develop vaccines to fight tuberculosis [TB], a company statement said Thursday," Agence France-Presse reports (3/15).
"I know I need this medicine to help lower my chance of cancer recurrence, but it makes my joints ache and stiff. It makes me feel old and I am not sure I can take this medication much longer."
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).
Researchers from Universidad Politécnica de Madrid have developed a new tool that provides standard and shared clinico-genomic data among European healthcare institutions.
› Verified 7 days ago
Julie S Francis, MD Dermatology Medicare: Medicare Enrolled Practice Location: 14030 Ne 24th St, Suite 202, Bellevue, WA 98007 Phone: 425-454-1104 Fax: 425-454-1290 | |
Samir P. Master, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1414 116th Ave Ne Ste E, Bellevue, WA 98004 Phone: 425-753-2918 | |
Keith Cameron Carlson, MD Dermatology Medicare: Medicare Enrolled Practice Location: 11511 Ne 10th St, Bellevue, WA 98004 Phone: 425-502-3000 | |
Andy J Chien, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 11511 Ne 10th St, Bellevue, WA 98004 Phone: 425-502-3000 Fax: 425-502-3589 | |
Dr. John P. Hackett, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1605 116th Ave Ne, Ste 102, Bellevue, WA 98004 Phone: 425-456-0709 Fax: 425-456-0358 | |
Dr. James Philip Harnisch, MD Dermatology Medicare: Medicare Enrolled Practice Location: 1600 116th Ave Ne, #306, Bellevue, WA 98004 Phone: 425-455-5111 Fax: 425-455-5113 | |
Dr. Anjeli Krishnan Isaac, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 11511 Ne 10th St, Bellevue, WA 98004 Phone: 425-502-3000 |